论文部分内容阅读
目的:探讨左卡尼汀联合促红细胞生成素治疗肾性贫血的临床疗效。方法:56例血液透析(hemodialysis,HD)伴有肾性贫血的尿毒症患者随机分为治疗组与对照组,每组28例。全部患者均应用促红细胞生成素(EPO)4000u,皮下注射,每周2次。治疗组于HD结束后静脉注射左卡尼汀1.0g,每周2次,疗程12周。所有患者分别记录治疗前和治疗开始后12周的血红蛋白、红细胞压积、C-反应蛋白。结果:两组患者经治疗后,贫血指标均得以改善,但治疗组升高的幅度更明显(P<0.05),炎症指标CRP水平均较治疗前下降,但治疗组下降的幅度更明显(P<0.05)。治疗组总有效率达到92.85%,亦明显高于对照组(P<0.05)。治疗组2例患者出现轻度恶心。结论:左卡尼汀可加强EPO的疗效。左卡尼汀联合EPO治疗肾性贫血安全有效。
Objective: To investigate the clinical efficacy of levocarnitine combined with erythropoietin in the treatment of renal anemia. Methods: Fifty-six patients with hemodialysis (HD) accompanied with renal anemia were randomly divided into treatment group and control group, with 28 cases in each group. All patients were given erythropoietin (EPO) 4000u, subcutaneous injection, 2 times a week. The treatment group received intravenous L-carnitine 1.0g at the end of HD twice a week for 12 weeks. All patients were recorded before treatment and 12 weeks after the start of hemoglobin, hematocrit, C-reactive protein. Results: After treatment, the anemia index was improved in both groups, but the increase in the treatment group was more obvious (P <0.05). The CRP level in the inflammatory index decreased compared with that before treatment, but the decrease in the treatment group was more obvious (P <0.05) <0.05). The total effective rate of the treatment group reached 92.85%, which was also significantly higher than that of the control group (P <0.05). Two patients in the treatment group had mild nausea. Conclusion: L-carnitine can enhance the efficacy of EPO. L-carnitine combined with EPO in the treatment of renal anemia is safe and effective.